[OPTIMAL 3] A phase III trial to evaluate the efficacy and safety of DHP107 (Liporaxel, oral paclitaxel) compared to Taxol (IV paclitaxel) as first line therapy in patients with recurrent or metastatic HER2 negative breast cancer (BC) (NCT03315364).

Abstract

TPS1106

Kim S-B; Zhang Q; Sun T; Seo JH; Lee KS; Kim T-Y; Tong Z; Park KH; Moon YW; Wang S

Journal of Clinical Oncology, Vol. 38, No. 15_suppl, pp. tps1106–tps1106

American Society of Clinical Oncology (ASCO)

May 20, 2020

10.1200/jco.2020.38.15_suppl.tps1106

0732-183X

Shusen Wang